Asian Tech Press (Oct 20)-- The Gates Foundation has committed up to $120 million to help low-income countries accelerate access to the investigational antiviral drug molnupiravir, the foundation said in a statement Tuesday.

Molnupiravir is a COVID-19 drug being developed in collaboration with Merck & Co., Inc. and Ridgeback Biotherapeutics.

The Foundation will consult with partners on how to use the funding to support efforts related to the development and production of a generic version of molnupiravir.